Tempest Therapeutics, Inc. (TPST) shareholders
TPSTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.38−0.00 (-0.29%)
Close on Nov 13, 2026Market cap $5.65MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
8.7%
1M of 15M shares
Institutional holders
21
4 new, 5 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
2 buys · 0 sales
Net bought $1.00M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Matthew Angel | 5,531,516 | 37.40% | 13D (active) amendment | Mar 24, 2026 |
| Sabby Management, LLC Joint filing with Hal Mintz (9.90%), Sabby Volatility Warrant Master Fund, Ltd. (9.90%) | 492,223 | 9.90% | 13G (passive) | Dec 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TPST | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Sabby Management, LLC | 511,286 | 3.45% | $567.53K | +493,430 | 0.51% |
| Versant Venture Management, LLC | 269,772 | 1.82% | $299.45K | – | 0.18% |
| Vanguard Capital Management LLC | 233,888 | 1.58% | $259.62K | – | 0.00% |
| Geode Capital Management, LLC | 86,625 | 0.59% | $96.16K | −365 | 0.00% |
| Vanguard Fiduciary Trust Co | 68,908 | 0.47% | $76.49K | – | 0.00% |
| BlackRock, Inc. | 39,068 | 0.26% | $43.37K | – | 0.00% |
| Squarepoint Ops LLC | 30,900 | 0.21% | $34.30K | New | 0.00% |
| Northern Trust Corp | 20,136 | 0.14% | $22.35K | +6,083 | 0.00% |
| Citadel Advisors LLC | 19,820 | 0.13% | $22.00K | New | 0.00% |
| UBS Group AG | 5,636 | 0.04% | $6.26K | +1,103 | 0.00% |
| Tower Research Capital LLC (TRC) | 3,922 | 0.03% | $4.35K | +1,132 | 0.00% |
| Morgan Stanley | 2,022 | 0.01% | $2.24K | −36 | 0.00% |
| Osaic Holdings, Inc. | 1,513 | 0.01% | $1.67K | −16 | 0.00% |
| Federation des caisses Desjardins du Quebec | 292 | 0.00% | $324 | – | 0.00% |
| Jones Financial Companies Lllp | 239 | 0.00% | $258 | – | 0.00% |
| Barclays PLC | 222 | 0.00% | $246 | New | 0.00% |
| SBI Securities Co., Ltd. | 56 | 0.00% | $62 | – | 0.00% |
| Royal Bank of Canada | 28 | 0.00% | $0 | +1 | 0.00% |
| Parallel Advisors, LLC | 18 | 0.00% | $20 | – | 0.00% |
| Caitong International Asset Management Co., Ltd | 3 | 0.00% | $3 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 21 | 1M | 8.7% | 4 / 5 | 3 / 5 | 1M | 0M |
| Q1 2026 | 22 | 1M | 5.3% | 5 / 3 | 3 / 2 | 0M | 0M |
| Q4 2025 | 21 | 1M | 5.3% | 6 / 3 | 4 / 2 | 0M | 0M |
| Q3 2025 | 17 | 1M | 4.0% | 3 / 7 | 1 / 4 | 0M | 0M |
| Q2 2025 | 18 | 1M | 6.4% | 3 / 4 | 8 / 9 | 1M | 0M |
| Q1 2025 | 24 | 0M | 3.1% | 1 / 9 | 1 / 11 | 0M | 0M |
| Q4 2024 | 35 | 1M | 3.5% | 14 / 9 | 4 / 7 | 0M | 0M |
| Q3 2024 | 28 | 0M | 1.5% | 9 / 4 | 3 / 4 | 0M | 0M |
| Q2 2024 | 24 | 0M | 1.1% | 5 / 6 | 5 / 10 | 0M | 0M |
| Q1 2024 | 30 | 0M | 1.0% | 5 / 10 | 6 / 7 | 0M | 0M |
| Q4 2023 | 32 | 0M | 1.2% | 16 / 9 | 5 / 8 | 0M | 0M |
| Q3 2023 | 24 | 0M | 1.8% | 5 / 3 | 7 / 3 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
7 funds held TPST in Q2 2026, 76% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TPST | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 128,944 | 0.87% | $143.13K | 0.00% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 104,944 | 0.71% | $116.49K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 50,985 | 0.34% | $78.01K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 15,677 | 0.11% | $23.99K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 7,495 | 0.05% | $11.47K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Matthew Angel | CEO and President, Director, 10% owner | 5,068,552 | 34.23% | Jun 23, 2026 |
| Stephen R. Brady | President and CEO, Director | 46,376 | 0.31% | Jan 6, 2025 |
| Stephanie Horn-Warnock | CFO, Treasurer, & Corp Sec. | – | – | Nov 3, 2026 |
| Nicholas Maestas | Chief Financial Officer | – | – | Apr 2, 2026 |
| Justin Trojanowski | Corporate Controller | 22,168 | 0.15% | Apr 2, 2026 |
| Samuel Whiting | Chief Medical Officer | 9,573 | 0.06% | Jan 6, 2025 |
| John W. Frederick | Director | 8,000 | 0.05% | Nov 2, 2026 |
| Nancy Freda Smith | Director | – | – | Oct 2, 2026 |
| John D. Yee | Director | – | – | Jun 17, 2026 |
| William Drake Richey | Director | 2,000 | 0.01% | Jun 8, 2026 |
| Michael Raab | Director | – | – | Jan 28, 2026 |
| Christine A. Pellizzari | Director | – | – | Jan 28, 2026 |
| Ronit Simantov | Director | – | – | Jan 28, 2026 |
| Geoffrey Nichol | Director | – | – | Jan 28, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Matthew Angel CEO and President, Director, 10% owner | Mar 24, 2026 | Buy | +231,482 | $2.16 | $500.00K | 231,482 |
| Matthew Angel CEO and President, Director, 10% owner | Mar 24, 2026 | Buy | +231,482 | $2.16 | $500.00K | 231,482 |
| Versant Venture Capital VI, L.P. 10% owner | Aug 12, 2024 | Sale | −387,999 | $1.10 | $426.80K | 209,941 |
| Versant Venture Capital VI, L.P. 10% owner | Aug 8, 2024 | Sale | −400,000 | $1.35 | $540.00K | 597,940 |
| Stephen R. Brady President and CEO, Director | Jul 3, 2024 | Buy | +35,000 | $2.11 | $73.85K | 46,376 |
| Samuel Whiting Chief Medical Officer | Jul 2, 2024 | Buy | +4,672 | $2.13 | $9.95K | 9,573 |
| Justin Trojanowski Corporate Controller | Jun 28, 2024 | Buy | +7,500 | $2.16 | $16.20K | 22,168 |
| Thomas Woiwode Director, 10% owner | Apr 29, 2022 | Buy | +2,118,644 | $2.36 | $5.00M | 2,118,644 |
| Thomas W. Dubensky President, Director | Jan 7, 2022 | Buy | +2,000 | $4.78 | $9.56K | 113,343 |
| Samuel Whiting Chief Medical Officer | Jan 6, 2022 | Buy | +1,700 | $4.80 | $8.16K | 1,901 |
| Samuel Whiting Chief Medical Officer | Jun 25, 2021 | Award | +201 | – | – | 201 |
| Thomas W. Dubensky President, Director | Jun 25, 2021 | Award | +111,343 | – | – | 111,343 |
| Thomas Woiwode Director, 10% owner | Jun 25, 2021 | Award | +997,940 | – | – | 997,940 |
| Thomas Woiwode Director, 10% owner | Jun 25, 2021 | Award | +1,171,094 | – | – | 1,171,094 |
| Thomas Woiwode Director, 10% owner | Jun 25, 2021 | Award | +7,377 | – | – | 7,377 |
| Pierre Lorenzo Corporate Controller | Jun 25, 2021 | Award | +53 | – | – | 53 |
| Stella Xu Director | Jun 25, 2021 | Award | +579,710 | – | – | 579,710 |
| Carol Giltner Gallagher Director | Dec 7, 2018 | Award | +23,684 | – | – | 23,684 |
| Carol Giltner Gallagher Director | Dec 7, 2018 | Award | +8,249 | – | – | 8,249 |
| Pharis Mohideen Chief Medical Officer | Dec 7, 2018 | Award | +7,440 | – | – | 7,440 |
| Mary Fisher Director | Dec 7, 2018 | Award | +355 | – | – | 3,319 |
| Richard Aldrich Director | Dec 7, 2018 | Award | +755 | – | – | 6,169 |
| Randall W. Whitcomb Director | Dec 7, 2018 | Award | +15,784 | – | – | 15,784 |
| Marc D. Kozin Director | Dec 7, 2018 | Award | +831 | – | – | 7,740 |
| Julia C. Owens President and CEO, Director | Dec 7, 2018 | Award | +74,400 | – | – | 74,400 |
| Marc D. Kozin Director | Sep 28, 2018 | Award | +16,014 | – | – | 103,647 |
| Mary Fisher Director | Sep 28, 2018 | Award | +6,851 | – | – | 44,460 |
| Richard Aldrich Director | Sep 28, 2018 | Award | +14,558 | – | – | 81,220 |
| Richard Aldrich Director | Jun 29, 2018 | Award | +11,709 | – | – | 66,662 |
| Marc D. Kozin Director | Jun 29, 2018 | Award | +12,880 | – | – | 87,633 |
| Mary Fisher Director | Jun 29, 2018 | Award | +5,510 | – | – | 37,609 |
| Marc D. Kozin Director | Mar 30, 2018 | Award | +14,411 | – | – | 74,753 |
| Mary Fisher Director | Mar 30, 2018 | Award | +6,165 | – | – | 32,099 |
| Richard Aldrich Director | Mar 30, 2018 | Award | +13,101 | – | – | 54,953 |
| Mary Fisher Director | Dec 29, 2017 | Award | +3,571 | – | – | 25,934 |
| Marc D. Kozin Director | Dec 29, 2017 | Award | +8,348 | – | – | 60,342 |
| Richard Aldrich Director | Dec 29, 2017 | Award | +7,589 | – | – | 41,852 |
| Mary Fisher Director | Sep 29, 2017 | Award | +3,521 | – | – | 22,363 |
| Marc D. Kozin Director | Sep 29, 2017 | Award | +8,230 | – | – | 51,994 |
| Richard Aldrich Director | Sep 29, 2017 | Award | +7,482 | – | – | 34,263 |
| Richard Aldrich Director | Jun 30, 2017 | Award | +6,810 | – | – | 26,781 |
| Marc D. Kozin Director | Jun 30, 2017 | Award | +6,477 | – | – | 43,764 |
| Mary Fisher Director | Jun 30, 2017 | Award | +3,205 | – | – | 18,842 |
| Thomas Malley Director | Jun 13, 2017 | Award | +7,873 | – | – | 204,981 |
| Thomas Malley Director | Mar 31, 2017 | Award | +7,085 | – | – | 197,108 |
| Mary Fisher Director | Mar 31, 2017 | Award | +2,673 | – | – | 15,637 |
| Marc D. Kozin Director | Mar 31, 2017 | Award | +5,180 | – | – | 37,287 |
| Richard Aldrich Director | Mar 31, 2017 | Award | +5,681 | – | – | 19,971 |
| Richard Aldrich Director | Dec 30, 2016 | Award | +6,944 | $1.53 | $10.62K | 14,290 |
| Thomas Malley Director | Dec 30, 2016 | Award | +8,660 | $1.53 | $13.25K | 190,023 |
| Marc D. Kozin Director | Dec 30, 2016 | Award | +6,331 | $1.53 | $9.69K | 32,107 |
| Mary Fisher Director | Dec 30, 2016 | Award | +3,267 | $1.53 | $5.00K | 12,964 |
| Christophe Couturier Chief Financial Officer | Dec 23, 2016 | Award | +300 | $1.44 | $432 | 50,900 |
| Richard Aldrich Director | Dec 22, 2016 | Gift | −154,519 | – | – | 7,346 |
| Richard Aldrich Director | Dec 22, 2016 | Gift | +154,519 | – | – | 330,000 |
| Richard Aldrich Director | Dec 13, 2016 | Gift | −645,842 | – | – | 161,865 |
| Richard Aldrich Director | Dec 13, 2016 | Gift | +645,842 | – | – | 668,192 |
| Richard Aldrich Director | Dec 7, 2016 | Gift | −200,000 | – | – | 0 |
| Richard Aldrich Director | Dec 7, 2016 | Gift | +200,000 | – | – | 807,707 |
| Thomas Malley Director | Sep 30, 2016 | Award | +1,850 | – | – | 181,363 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
2.67%
0M shares short
Days to cover
1.9
At 0M shares a day
Change since last report
-22.9%
From 0M shares
Short volume, 20 days
51.0%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Tempest Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 1,264,363 shares on Sep 17, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Versant Venture Capital VI, L.P. Owner | Aug 13, 2024 | 387,999 | $426.99K | Aug 12, 2024 | private offering |
| Versant Venture Capital VI, L.P. 10% Stockholder | Aug 9, 2024 | 400,000 | $7.21M | Aug 8, 2024 | private offering |
| Dubensky Thomas W. Officer, Director | Nov 2, 2023 | 30,000 | $131.45K | Oct 25, 2023 | early exercise |
See a number that looks wrong?